お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:TCR様抗体・TCR融合タンパク質・細胞透過性生物製剤によるドラッガブルな細胞内標的:産業分析
市場調査レポート
商品コード
600758

TCR様抗体・TCR融合タンパク質・細胞透過性生物製剤によるドラッガブルな細胞内標的:産業分析

Intracellular Targets Made Druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: An Industry Analysis of Technologies, Stakeholders, Deals & Trends

出版日: | 発行: La Merie Publishing | ページ情報: 英文 251 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.16円
TCR様抗体・TCR融合タンパク質・細胞透過性生物製剤によるドラッガブルな細胞内標的:産業分析
出版日: 2018年01月22日
発行: La Merie Publishing
ページ情報: 英文 251 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、TCR様抗体・TCR融合タンパク質・細胞透過性生物製剤によるドラッガブルな細胞内標的について調査分析し、最新の主要技術のほか、主要製品候補のプロファイル、技術企業など、体系的な情報を提供しています。

第1章 エグゼクティブサマリー

第2章 イントロダクション・概要

第3章 背景

第4章 技術のプロファイル

  • 概要・考察
  • 細胞内標的の発見の技術
  • TCRの発見の技術
  • TCRL抗体の生成の技術
  • TCR融合タンパク質の生成の技術
  • 細胞透過性生物製剤の生成の技術

第5章 パイプライン分析と製品プロファイル

  • 製品プロファイルとパイプライン分析
  • 主要なTCRL抗体・TCR融合タンパク質のプロファイル
  • 主要な細胞透過性ペプチド・タンパク質・抗体のプロファイル

第6章 ステークホルダー分析と企業プロファイル

  • ステークホルダー分析と企業プロファイルの概要
  • 企業プロファイル:TCR融合タンパク質技術
  • 企業プロファイル:TCR様抗体技術
  • 企業プロファイル:TCR融合タンパク質技術/TCRL抗体技術
  • 企業プロファイル:TCR発見技術 (T細胞療法)
  • 企業プロファイル:細胞透過性ペプチド・タンパク質/抗体技術、など

第7章 取引と資金調達

第8章 動向と見通し

第9章 参考資料

目次
Product Code: LMFR0025

It is estimated that there are 3-4 times more intracellular targets than surface protein targets. However, these intracellular cancer targets are not accessible to traditional monoclonal antibody (mAb) therapies. Since many of these targets are not enzymes or surface receptoers with readily druggable pockets, these important oncogenic proteins cannot be easily inhibited with small molecules. Thus, intracellular cancer-specific proteins, such as mutated oncogene products, transcription factors, protein adapters, and other nontraditional targets, remain inaccessible to current technologies used for FDA-approved drugs.

Therefore, novel technologies are needed to address historically undruggable targets and complex mechanisms, such as intracellular protein-protein interactions like p53 or Ras, Β-catenin and Myc.

image1

This report "Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends" brings you up-to-date regarding key technologies

  • for identification and validation of intracellular targets,
  • for generation of T-cell receptors (TCR) and TCR fusion proteins,
  • for discovery of TCR-like antibodies, and
  • for construction of cell-penetrating peptides, proteins and antibodies.

The report furthermore describes the profiles of leading product candidates created by these technologies. The technology companies are presented and analyzed. Deals between Big Pharma and technology companies as well as collaboration and licensing deals between technology companies are highlighted. The value of technologies and product candidates are discussed regarding company acquisition prices, economic deal terms and financing rounds.

What will you find in the report?

Description and comparison of technologies for

  • Discovery and validation of intracellular targets;
  • Discovery and optimization of T-Cell Receptors (TCRs);
  • Generation of TCR-like or TCR-mimic antibodies;
  • Generation of TCR fusion proteins
  • Generation of cell-penetrating peptides, proteins and antibodies.

Presentation and discussion of profiles of selected product candidates:

  • TCRL antibodies and TCR fusion proteins; and
  • Cell-penetrating peptides, miniproteins and single domain and Ig antibodies

Stakeholder analysis based on profiles of 45 companies active in the field

Analysis of partnering deals and financing rounds

Table of Contents

1 Executive Summary

2 Introduction & Overview

3 Background

4 Technology Profiles

  • 4.1 Overview & Discussion
    • 4.1.1 Intracellular Target Discovery
    • 4.1.2 TCR Discovery Technologies
    • 4.1.3 Generation of TCR-like Antibodies
    • 4.1.4 Generation of TCR Fusion Proteins against Intracellular Targets
    • 4.1.5 Generation of Cell Penetrating Biologics against Intracellular Targets
  • 4.2 Technologies for Discovery of Intracellular Targets
    • 4.2.1 XPRESIDENT
    • 4.2.2 Targets for TCRs (Immunocore)
    • 4.2.3 Phosphopeptide Library
    • 4.2.4 HTS Platform for Neoantigen Identification
    • 4.2.5 ECLIPSE Platform
    • 4.2.6 EpiTarget Platform
    • 4.2.7 Soluble HLA (sHLA) Molecules
    • 4.2.8 Phagemers & SSIp display
    • 4.2.9 Peptide/MHC Complexes
    • 4.2.10 TCR Target Discovery
  • 4.3 Technologies for Discovery of TCRs
    • 4.3.1 Naturally Selected TCRs
    • 4.3.2 TCRs by ImmTAC Technology
    • 4.3.3 HTS for TUMAP-Restricted TCRs
    • 4.3.4 Natural TCR Library
    • 4.3.5 Sleeping-Beauty Expression System
    • 4.3.6 TCR-GENerator
    • 4.3.7 T-Rx Mammalian TCR Display
    • 4.3.8 Single Cell Sequencing Platform
    • 4.3.9 Immune Repertoire Capture
    • 4.3.10 Combinatorial TCR Exchange (CTE)
    • 4.3.11 VelociT for T-Cell Receptor Discovery
  • 4.4 Technologies for Generation of TCRL Antibodies
    • 4.4.1 TandAb
    • 4.4.2 BiTE
    • 4.4.3 E-Alpha Phage Display
    • 4.4.4 HuTARG Protein Engineering
    • 4.4.5 MAR & TriTE
    • 4.4.6 TCRL Antibodies
    • 4.4.7 TCRm Antibodies
    • 4.4.8 Ylanthia Fab library
    • 4.4.9 TCRL ADCs
  • 4.5 Technologies for Generation of TCR Fusion Proteins
    • 4.5.1 ImmTAC
    • 4.5.2 TCR Bispecifics
    • 4.5.3 STAR
  • 4.6 Technologies for Generation of Cell Penetrating Biologics
    • 4.6.1 Cell-Penetrating alpha Bodies
    • 4.6.2 Anti-DNA Autoantibodies
    • 4.6.3 Cell Penetrating Mini Proteins (CPMP)
    • 4.6.4 Feldan Shuttle
    • 4.6.5 Shark VNARs
    • 4.6.6 iMab
    • 4.6.7 iTABs
    • 4.6.8 Stapled Peptides
    • 4.6.9 Single Domain Antibodies

5 Pipeline Analysis and Product Profiles

  • 5.1 Overview Product Profiles and Pipeline Discussion
  • 5.2 Profiles of Selected TCRL Antibodies & TCR Fusion Proteins
    • 5.2.1 IMCgp100
    • 5.2.2 ALT-801
    • 5.2.3 H8F4
    • 5.2.4 MMP1-003 TandAb
    • 5.2.5 ESK1 & ESKM
    • 5.2.6 RL1B
  • 5.3 Profiles of Selected Cell Penetrating Peptides, Proteins & Antibodies
    • 5.3.1 ALRN-6924
    • 5.3.2 Anti-Mcl-1 CPAB
    • 5.3.3 PAT-DX1 & Other Deoxymabs
    • 5.3.4 RT11-i
    • 5.3.5 SBT-100

6 Stakeholder Analysis & Company Profiles

  • 6.1 Stakeholder Analysis and Overview of Company Profiles
  • 6.2 Profiles of Companies with Target Discovery and TCR Fusion Protein Technologies
    • 6.2.1 Agenus
    • 6.2.2 Atreca
    • 6.2.3 Immatics Biotechnologies
    • 6.2.4 Immunocore
    • 6.2.5 Regeneron Pharmaceuticals
  • 6.3 Profiles of Companies with Target Discovery and TCR-Like Antibody Technologies
    • 6.3.1 AbeXXa
    • 6.3.2 Adicet Bio
    • 6.3.3 MD Anderson Cancer Center
    • 6.3.4 Pure MHC
  • 6.4 Profiles of Companies with TCR Fusion Protein and/or TCRL Antibody Technologies
    • 6.4.1 Affimed Therapeutics
    • 6.4.2 NantCell (Altor Bioscience)
    • 6.4.3 Eureka Therapeutics
    • 6.4.4 Innovative Targeting Solutions (ITS)
    • 6.4.5 Morphosys
    • 6.4.6 Receptor Logic (now Pure MHC)
    • 6.4.7 Timmune Biotech
  • 6.5 Profiles of Companies with TCR Discovery Technologies only used for T-Cell Therapy
    • 6.5.1 BioNTech
    • 6.5.2 Gadeta
    • 6.5.3 Gilead Sciences (Kite Pharma)
    • 6.5.4 Juno Therapeutics
    • 6.5.5 Medigene
    • 6.5.6 ZIOPHARM Oncology
  • 6.6 Profiles of Companies with Cell Penetrating (CP) Peptide, Protein or Antibody Technologies
    • 6.6.1 Aileron Therapeutics
    • 6.6.2 Complix
    • 6.6.3 Elasmogen
    • 6.6.4 Feldan Therapeutics
    • 6.6.5 Fog Pharmaceuticals
    • 6.6.6 Orum Pharmaceuticals
    • 6.6.7 Patrys
    • 6.6.8 Singh Biotechnology
    • 6.6.9 Sorrento Therapeutics & LA Cell
  • 6.7 Profiles of Big Pharma & Biotech Companies Active in the Intracellular Target and TCR & Cell Penetrating Biologics Field
    • 6.7.1 AbbVie
    • 6.7.2 Amgen
    • 6.7.3 Astellas Pharma
    • 6.7.4 AstraZeneca
    • 6.7.5 Boehringer Ingelheim
    • 6.7.6 Eli Lilly
    • 6.7.7 GlaxoSmith-Kline
    • 6.7.8 Janssen Biotech
    • 6.7.9 Merck
    • 6.7.10 Novartis
    • 6.7.11 Roche
  • 6.8 Profiles of Other Companies with Stakes in the Field of Intracellular Targets and TCR & Cell Penetrating Biologics
    • 6.8.1 Nextera
    • 6.8.2 Xencor
    • 6.8.3 Zymeworks

7 Deals & Financing

  • 7.1 Partnering Deals between Big Pharma and Technology Companies
  • 7.2 Acquisitions of Technology Companies
  • 7.3 Collaboration and Licensing Deals between Technology Companies
  • 7.4 Financing Sources of Technology Companies

8 Trends & Outlook

10 References

Tables in the report

  • Overview of Corporate Technologies to Discover Intracellular Targets for TCRs
  • Overview of Corporate Technologies to Discover Therapeutic TCRs
  • Overview of Technologies for Generation of TCRL Antibodies against Intracellular Targets
  • Overview of Technologies for Generation of TCR Fusion Proteins against Intracellular Targets
  • Overview of Technologies for Generation of Cell Penetrating Biologics against Intracellular Targets
  • Affinity Enhancement of TCRs by Immunocore technology
  • Examples of Direct Identification and Confirmation of Class I MHC-Peptide Epitopes on Cells with T-Cell Receptor Mimic Antibodies
  • Profiles of Selected TCRL Antibodies & TCR Fusion Proteins
  • Profiles of Selected Cell Penetrating Peptides, Proteins & Antibodies
  • Clinical Studies with IMCgp100
  • Profiles of Companies with Target Discovery and TCR Fusion Protein Technologies
  • Profiles of Companies with Target Discovery and TCR-Like Antibody Technologies
  • Profiles of Companies with TCR Fusion Protein and/or TCRL Antibody Technologies
  • Profiles of Companies with TCR Discovery Technologies only used for T-Cell Therapy
  • Profiles of Companies with Cell Penetrating (CP) Peptide, Protein or Antibody Technologies
  • Profiles of Big Pharma & Biotech Companies Active in the Intracellular Target and TCR & Cell Penetrating Biologics Field
  • Profiles of Other Companies with Stakes in the Field of Intracellular Targets and TCR & Cell Penetrating Biologics
  • Antibody-based immunotherapeutics against pMHCs* discovered by immatics' XPRESIDENT technology
  • Immunocore's Proprietary and Partnered Pipeline of TCR Fusion Proteins
  • Goals and Terms of Immunocore's Partnering Deals for ImmTAC Technology
  • Innovative Targeting Solutions and Drug Candidates from HuTARG Platform
  • Examples of Direct Identification and Confirmation of Class I MHC-Peptide Epitopes on Cells with T-Cell Receptor Mimic Antibodies
  • Pipeline sdAbs from Singh Biotechnology
  • Collaboration and Licensing Agreements between Big Pharma/Biotech and Technology Companies for Intracellular Targets and Therapeutic Biologics
  • Acquisition of Technology Companies in the Field
  • Collaboration and Licensing Agreements between Technology Companies
  • Financing Sources of Technology Companies in the Field

Companies mentioned in the report

  • AbbVie
  • AbeXXa Biologics
  • Adicet Bio (Applied Immune Technologies)
  • Affimed Therapeutics
  • Agenus
  • Aileron Therapeutics
  • Amgen
  • Astellas Pharma
  • AstraZeneca
  • Atreca
  • BioNTech
  • Boehringer Ingelheim
  • Complix
  • Elasmogen
  • Eli Lilly
  • Eureka Therapeutics
  • Feldan Therapeutics
  • Fog Pharmaceuticals
  • Gadeta
  • Gilead Sciences (Kite Pharma)
  • GlaxoSmith-Kline
  • Immatics Biotechnologies
  • Immunocore
  • Innovative Targeting Solutions (ITS)
  • Janssen Biotech
  • Juno Therapeutics
  • MD Anderson Cancer Center
  • Medigene
  • Merck
  • Morphosys
  • NantCell (Altor Bioscience)
  • Nextera
  • Novartis
  • Orum Pharmaceuticals
  • Patrys
  • Pure MHC
  • Pure MHC
  • Receptor Logic (now Pure MHC)
  • Regeneron Pharmaceuticals
  • Roche
  • Singh Biotechnology
  • Sorrento Therapeutics & LA Cell
  • Timmune Biotech
  • Xencor
  • ZIOPHARM Oncology
  • Zymeworks
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.